Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹77.01 - ₹278.60
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹6.34B
Enterprise Value₹4.06B
Total Cash (Recent Filing)₹20.25M
Total Debt (Recent Filing)₹374.33M
Price to Earnings (P/E)56.1
Beta0.66
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.69
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue GrowthSustained multi-year revenue growth signals the company has built recurring demand and commercial scale across markets. Over a 2–6 month horizon this underpinning supports better factory utilization, purchasing leverage and the potential to convert scale into steadier margins as execution normalizes.
Reasonable Balance Sheet And Equity BaseA steadily building equity base and moderate leverage provide structural financial resilience. This durability supports investment in manufacturing, regulatory compliance and export growth, reducing bankruptcy risk and enabling medium-term strategic moves without immediate reliance on external capital.
Historical Return-on-equity StrengthStrong ROE in 2023 demonstrates historical ability to convert capital into profits and reflects efficient asset and working-capital use. That track record suggests management can generate attractive returns when operating conditions stabilize, aiding medium-term shareholder value creation.
Bears Say
Persistently Negative Free Cash FlowNegative free cash flow across most years indicates cash is being absorbed by capex, working capital or other uses despite reported profits. Over months this reduces financial flexibility, raises reliance on external funding, and limits the firm's ability to self-finance dividends or strategic investments.
Margin And Earnings VolatilityMaterial margin compression after a period of very strong margins points to volatile earnings quality and pricing or cost pressures. Such structural variability makes cash-flow forecasting harder, weakens predictability of returns, and complicates long-term planning for R&D or product expansion.
Rising Debt TrendAn increasing debt load raises leverage risk and amplifies sensitivity to cash-flow shortfalls—especially given persistent negative FCF. Over a medium horizon higher interest and repayment obligations can constrain reinvestment, limit M&A flexibility and increase refinancing risk during stress periods.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹77.01 and its highest was ₹278.60 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹6.34B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on May 29, 2026. The company reported ₹1.16 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.16.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹1.16 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
Technical Analysis
Hikal Limited
―
Kilitch Drugs (India) Limited
―
Sanofi India Limited
―
Supriya Lifescience Limited
―
Wockhardt Limited
―